Pamela Turk
Primary Care · Douglas, GANPI 1972667954
Payments from drug & device makers
Across 691 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Pfizer$1K
- Amgen$1K
- Corcept Therapeutics$1K
- AstraZeneca$918
- plus $7K from 43 others
What the payments were for
- Food & beverage$14,25598%
- Education$3212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,576 in reported general payments places this provider in the 95th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 25 | $1,029,905 |
| OzempicSemaglutide | 187 | $202,274 |
| FarxigaDapagliflozin Propanediol | 215 | $150,608 |
| MounjaroTirzepatide | 107 | $114,850 |
| EliquisApixaban | 152 | $113,261 |
| VraylarCariprazine Hcl | 77 | $110,332 |
| JardianceEmpagliflozin | 100 | $78,535 |
| LinzessLinaclotide | 116 | $78,471 |
| TrulicityDulaglutide | 51 | $61,139 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 76 | $49,901 |
| MyrbetriqMirabegron | 76 | $40,205 |
| RexultiBrexpiprazole | 20 | $35,076 |
| EntrestoSacubitril/Valsartan | 52 | $34,369 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $32,865 |
| XareltoRivaroxaban | 33 | $24,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,004 | $1,029,90525 claims |
| Novo NordiskOzempic, Rybelsus | $1,379 | $213,841198 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,530 | $193,722274 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $918 | $191,475291 claims |
| Lilly USA, LLCMounjaro, Trulicity | $200 | $175,990158 claims |
| PfizerEliquis, Nurtec Odt | $1,278 | $136,395167 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $145 | $128,436176 claims |
| Astellas Pharma US IncMyrbetriq | $688 | $40,20576 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $892 | $36,83173 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $390 | $35,07620 claims |
| NovartisEntresto | $207 | $34,36952 claims |
| Johnson & JohnsonXarelto | $252 | $24,10433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 primary care providers in Georgia.
Other primary care in Douglas
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
- Erin EverettAtlanta$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.